Objective: To assess the degree of osteopenia in children with celiac disease (CD) at the time of diagnosis and the effect of a gluten-free diet (GFD). Design: Longitudinal and prospective study. Subjets: In total, 24 children (18 girls, six boys) diagnosed with CD by means of an intestinal biopsy were included in the study. Mean7s.d. age was 4.974.3 years. In all, 16 patients were under (2.2070.82 year) and eight were over the age of 4 years (10.3072.90 year). The time between the first symptoms and diagnosis was 17.30724.70 months (range: 2-109 months). Spine bone mineral content (BMC), area and bone mineral density (BMD) were measured by DXA at baseline and 1.1770.93 years after GFD. Results: Before treatment, mean7s.d. BMD was 0.4670.13 g/cm 2 , the BMD Z-score was À1.3671.20, and was below À1 s.d. in 14 patients (58%). BMC, area and BMD increased significantly on GFD. BMD increased from 0.4670.13 to 0.5570.13 g/cm 2 (Po0.001). BMD Z-score improved from À1.3671.20 to À0.2371.20 after GFD. However, BMD increased more than 1 s.d. in 15 of the 16 children under the age of 4 years, a similar increase was only observed in four of the eight children aged more than 4 years, some of whom did not follow GFD strictly. Height and weight increased significantly with GFD (Po0.001) and the increase correlated positively with the increase in BMD. Conclusions: Axial BMD below À1 s.d. was found in 58% of children with celiac disease. Axial bone mass reverted to normal values in most children under the age of 4, who had low bone mass, all of whom followed GFD strictly.
Introduction
Celiac disease (CD) is one of the most frequent causes of intestinal malabsorption during childhood (Walker-Smith). While in 1985 the incidence of CD in Argentina was 1/1300 (De Rosa, 1993) , a study carried out in 2001 revealed that 1/160 adult suffered the disease (Gomez et al., 2001) , similar to the observations made in other countries (Walker-Smith). The age of pediatric celiac patients at diagnosis was less than 2 years in 40%, between 2 and 5 years in 40% and over 5 years in 20% (De Rosa et al., 1999) of patients.
Osteopenia and rickets have been reported to be a consequence of the disease (Exner et al., 1978; Cimaz et al., 2000) . Celiac disease impairs intestinal absorption of several nutrients including calcium, which in turn compromises bone mass.
After following a gluten-free diet (GFD), intestinal absorption is restored. BMD has been found to increase after GFD in adults, without reaching normal values (Mautalen et al., 1997) . Although several studies have assessed bone mass in children with celiac disease (Exner et al., 1978; Mora et al., 1993; Scotta et al., 1997; Mora et al., 1998 Mora et al., , 1999 Rea et al., 1998; Muzzo et al., 2000) , most of them comprised a population of older patients.
While on GFD, children with CD experience a complete catch-up growth in height and weight. Bone mass improves when children follow GFD (Mora et al., 1993; Scotta et al., 1997; Mora et al., 1998 Mora et al., , 1999 Rea et al., 1998; Muzzo et al., 2000) . However, it is not definitively established whether GFD restores bone mass to normal values. The purpose of this study was to assess bone status in a group of 24 children with celiac disease -most of whom were diagnosed before the age of 4 years -and to evaluate prospectively the effect of GFD on bone mass.
Patients and methods
We studied 24 Caucasian children, 18 girls and six boys, seen consecutively at our Hospital between 1995 and 2001. A 7.2-year-old girl was excluded from the study since she presented hypothyroidism and diabetes, which affected response.
In all patients, diagnosis of CD was made by intestinal peroral biopsy performed with a Crosby Kugler or Watson capsule. Histologic evaluation showed subtotal or total villous atrophy.
The mean7s.d. age at baseline prior to GFD was 4.9074.30 years (range 1-11.7 years). In all patients, 16 children were under (2.2070.82 years), and eight patients were over the age of 4 years (10.3072.90 years).
The time between symptoms and diagnosis was 17725 months. It was shorter in very young children: 10710 vs 3477 months in children older than 4 years. The most frequent clinical features at the first visit were chronic diarrhea, growth retardation, and abdominal distention. Children older than 4 years also complained of pain in the knees or weakness when walking.
The patients' clothes and shoes were removed for height and weight determinations. Standard deviation of height and weight was estimated using standard charts for Argentinian children (Lejarraga and Orfila, 1987) .
Bone mineral content (BMC), area and Bone mineral density (BMD) of the lumbar spine (L1-L4) were measured by dual X-ray absorptiometry (DXA) Hologic, QDR 1000) in all patients. Although most of the patients were very young, none required restraining procedures during the study -most of the infants were allowed to have their feeding bottle. The coefficient of variation of BMD using a spine phantom was 0.64%. BMD was expressed in g/cm 2 and as Z-score (Z-score is the deviation of the patient's value from the mean divided by the Standard deviation of values obtained in a population of children of the same age and gender) (Glastre et al., 1990) . Our laboratory found BMD values of Argentinian adults to be similar to those observed in American adults (Vega et al., 1993) . Since the available normal BMD reference values for Argentine children were not obtained using the same equipment (Hologic, QDR 1000), results were compared to normal value charts obtained with this equipment in a population of French children (Glastre et al., 1990) . This is an obvious limitation of our definition of 'normal value'. Osteopenia or low bone mineral density was defined as a condition in which BMD-Z-score was below À1. (Saggese et al., 2001) . Although the study protocol included follow-up spine determinations 1 year after the onset of treatment, this was not possible in some cases. The mean (7s.d.) time interval between determinations was 1.1770.93 years after commencing GFD (range: 3 months to 3.9 years). Weight and height were recorded at the same time.
Biochemical parameters were determined before starting GFD. Serum calcium was measured by atomic absorption spectrophotometry (normal value: 2.20-2.70 mmol/l). Serum phosphate and serum alkaline phosphatase (AP) were measured by autoanalyzer Hitachi 911 (AP n.v: o550 IU/l). A total amount of 25 hydroxyvitamin D was measured by inhouse radiocompetitive protein-binding assay (Delvin et al., 1980). (n.v: 92.5722 .5 nmol/l in summer and 62.57 25 nmol/l in winter). The mean interassay CV was 10%. Intact PTH was measured by IRMA (normal: 12-72 pg/ml). A random fasting urine sample was collected to determine Calcium/Creatinine ratio (UCa/Creat, n.v o0.59 mmol/ mmol).
Patients received 1000 IU of vitamin D per day during the first 3 months of treatment, after which vitamin D was discontinued. Patients did not receive oral calcium supplementation, they were advised by nutritional assessment to follow GFD strictly and to consume dairy products to ensure adequate calcium intake.
Institutional review
All the parents gave informed consent. The study was performed in accordance with the Declaration of Helsinki and was approved by the ethics committee of the institution.
Statistical analysis. Data are expressed as mean7s.d. Statistic analysis was performed to calculate the relationship between area, BMC, BMD, weight and height. Statistical significance was considered at the 5% level (Pp0.05, two sides). Mann-Whitney and Wilcoxon tests were used to compare difference between younger and older children. The correlation between variables with a no normal distribution assessed by Shapiro Wilk test has been made with r Spearman's correlation coefficient.
Results

Baseline studies
Height and weight Z-scores of the whole group were À1.4471.09 and À1.7170.93, respectively (Table 1) . Height Z-score was below À2 in eight children, and weight Z-score was below À2 in eleven. In all, 11 patients (46%) had a weight Z-score below À2, nine (38%) with concomitant short stature (Z-score À2.5070.80). Average baseline BMD Zscore of the total group was À1.3671.20 (Table 1) . In all, 14 children (58%) had a basal BMD Z-score below À1 s.d. (Figure 1 ). Four patients (17%) had severe osteopenia (BMD Z-score: À3.1070.80).
As in normal children, there was a significant correlation between basal BMC, area and BMD and weight (r: 0.97, r: 0.97 and r: 0.91, Po0.001) and between BMC, area and BMD and height (r: 0.90, r: 0.93 and r: 0.88, Po0.001). We found no relation between BMD and subtotal or total villous atrophy determined by histologic examination of the intestinal biopsy.
Serum calcium was 2.3370.25 mmol/l (Table 2) . Slight hypocalcemia was observed in 7/24 patients (2.057 0.07 mmol/l). Serum alkaline phosphatase was 3957 114 IU/l. Only one patient had a value above the normal range. Serum phosphate and creatinine were within normal range. Serum levels of 25 OH D and intact PTH were within normal values (67.5723 nmol/l and 39721 pg/ml, respectively). UCa/Creatinine ratio was 0.6070.60 mmol/mmol, the upper normal limit.
Treatment
Bone mass BMC, area and BMD increased significantly after GFD (Po0.02, ) (Zanchetta et al., 1995) . The increment in lumbar spine BMC, area and BMD correlated significantly (r Spearman's correlation coefficient) with the increase observed in height (0.63 Po0.002, 0.66 Po0.001 and r: 0.64, Po0.001) and weight (0.61, Po0.003, 0.55, Po0.005 and r: 0.47, Po0.01).
In the group of very young children, BMC, area and BMD also increased significantly (Table 3) . BMD increased from 0.3970.06 to 0.4970.05 g/cm 2 , Po0.022. BMD Z-score increased from À1.2571.10 to þ 0.2070.84, throughout a period of 1.070.93 years. BMD was found to increase more than 1 s.d. in 15 out of 16 children (Figure 2 ). Six children, aged between 1 and 3 years old, increased their spine bone mass into the normal range within 3-7 months on GFD. They were also measured later and they remained into the normal range.
As regards children older than 4 years, BMC, area and BMD increased significantly (Table 3) . BMD increased from 0.5870.14 to 0.6870.17, Po0.024. BMD Z-score increased from À1.6 to À1.1. Bone mass reached more than À1 s.d. in 50% of patients.
Height
Height Z-score of the whole group was À1.4471.09 before treatment and À0.6271.34 after GFD. Height was 97.80725.70 before GFD and 107.20725.20 cm after GFD 
Discussion
Celiac disease impairs intestinal absorption of several nutrients including calcium. This decreased absorption of calcium compromises bone mass. BMD has been reported to increase in adults, without reaching normal values, after treatment with GFD (Mautalen et al., 1997) . Numerous studies have assessed bone mass in children with CD (Exner et al., 1978; Mora et al., 1993; Scotta et al., 1997; Mora et al., 1998; Rea et al., 1998; Mora et al., 1999; Muzzo et al., 2000) . Most authors reported decreased spine and whole-body BMD before treatment with gluten-free diet. Their observations were made on groups of older children with CD (Scotta et al., 1997; Mora et al., 1999; Muzzo et al., 2000; Barera et al., 2004) . Szathmari et al. (2001) reported that celiac children and adolescent after being on gluten-free diet for three or more years, have normal or even higher radius mineral density values than controls, but the bone size remained reduced. The present report is the first longitudinal study to evaluate bone mass in very young celiac children. The increment of BMC was two-fold greater than the increment of the area, indicating that GFD treatment increases bone mineralization in addition to the increment due to bone growth.
In the young and the very young patients, average increment of the spine BMD was 0.10 g/cm 2 during the approximately 14 months period of observation, while in the normal population, reports of the literature, indicate increments of approximately 0.05 g/cm 2 for 2 years of age and approximately 0.02 g/cm 2 at 10 years of age during 1 year period (Zanchetta et al., 1995) . As shown by the final follow-up determinations, 93% of children who started treatment before the age of 4 years reached normal spine BMD values, as opposed to only 50 % Osteopenia in celiac disease. Effect of gluten-free diet C Tau et al of those who were older at the time of diagnosis and treatment. Mora et al. (1998) found spine and whole-body BMD of children with celiac disease to increase 0.06 g/cm 2 and 0.05 g/cm 2 , respectively, after 1.470.04 years on GFD. According to these authors, BMD was normal at the end of the study.
The length of treatment needed to restore bone mass has not been clearly established. It was recently reported that 1year of GFD is sufficient to obtain complete restoration of BMD (Rea et al., 1998) . Final determinations were not performed at the same time points on all our patients, so that length of treatment varied. However, we found that some patients showed recovery of bone mass after only 3-7 months on GFD, whereas others only showed recovery after 1.5 years therapy.
Compared with other reports, the symptomatic period before diagnosis was longer in our patients (17 months). Rea et al. (1998) , for example, observed a mean period of 5.3 months between first symptoms and diagnosis. It has been suggested that patients with a shorter symptomatic period, recover more completely than those suffering longer periods of untreated CD (Scotta et al., 1997) . Sdepanian et al. (2003) found that BMD was significantly lower in adolescent with CD on GFD compared with controls but not in children with CD compared with controls; the authors attributed these findings to the longer time between symptoms and diagnosis in adolescents, due to which they suffer more malnutrition and more bone damage than children. In our study, children older than 4 years of age compared with young children suffered a longer period between symptoms and diagnosis. Only half of them recovered completely on GFD. In our study, the patients with malnutrition had low lumbar bone mass.
Hypocalcemia and vitamin D deficiency have been reported in patients with celiac disease (Rakover et al., 1994) . In our study, slight hypocalcemia has been observed in seven patients before GFD and it was not related with vitamin D deficiency because children had serum 25(OH)D within normal range. Their slight hypocalcemia could be related with chronic calcium malabsorption. Besides, patients received 1000 IU of vitamin D per day during the first 3 months of treatment, after which vitamin D was discontinued. BMD measurements have been performed during the first month of treatment, so it is unprobable that bone mass recovery could be originated by this vitamin D supplementation. Patients did not receive any oral calcium supplementation. Previous studies support the importance of dietary products in children with celiac disease. Some reports encourage calcium supplementation in children with CD (Muzzo et al., 2000) .
Increasing calcium intake during childhood and adolescence is associated with greater bone mass gain and higher peak of bone mass (Sentipal et al., 1991) . The intake of calcium and proteins should be considered for this bone mass accumulation in children with celiac disease. Low protein intake could be detrimental to skeletal integrity by lowering the production of IGF-I and GH hepatic production (Isley et al., 1983) . IGF-I is essential for bone longitudinal growth, plays a role in trabecular and cortical bone formation, and a relative deficiency may result in reduction in skeletal longitudinal growth. In experimental animals, IGF-I administration increased the external diameter of long bones (Ammann et al., 1993) . A reduction of growth hormone-binding proteins has also been described during the active phase of celiac disease which disappeared during the gluten-free diet (Federico et al., 1997) .
The limitations of our study arise mainly from the small number of patients, the lack of local normal BMD values, and the variation in final follow-up determination timepoints. In spite of these limitations, the results of this study strongly suggest that, contrary to what has been observed in adults, bone mass is restored in children as a result of the treatment. These observations may be worth taking into consideration so that children with celiac disease may attain normal peak bone mass if the diagnosis and treatment are made before puberty, thereby preventing osteopenia in adult life.
